Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Cox regression analyses in two subgroups divided by the median HER2 expression value.

From: Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

Cohort subset> Variable Hazard ratio 95%C.I. P-value
Log10HER2 expression • 1.799* Log10 HER2 expression 0.06 0.01 - 0.51 0.010
(n = 37) Hormone receptor status 0.39 0.05 - 2.86 0.354
  Brain mets 0.14 0.02 - 0.87 0.034
Log10HER2 expression < 1.799* Log10 HER2 expression 16.0 1.64 - 155.9 0.017
(n = 37) Hormone receptor status 0.20 0.03 - 1.57 0.125
  Brain mets 0.04 0.01 - 0.28 0.001
  1. * Median (50 percentile) value of Log10HER2 expression measurements